Alkem Labs Launches Vonzai, the Next Generation Therapy for APD Management

Alkem Labs, one of the leaders in the gastro segment with well-known products like PAN, Pan-D, and Obetohep has announced the launch of the next-generation molecule, Vonoprazan in India under the brand name Vonzai. Vonzai will be launched under its newly established Gastrokem division. In a non-exclusive patent licensing with Takeda, Alkem aims to bring this novel treatment to the Indian market.

Vonzai tablets containing Vonoprazan are available in two dosage strengths: 10 mg and 20 mg. Vonoprazan fumarate has been approved by DCGI for the treatment of reflux esophagitis (RE), gastric ulcers and duodenal ulcers.

Studies indicate that P-CABs can help to bridge current therapeutic gaps through their longer half-life, greater effectiveness against nocturnal acid breakthrough and meal-independent dosing.

Unlike conventional therapies, P-CABs are acid-stable, do not require an enteric coating, and act immediately on proton pump, eliminating the need for pre-meal dosing. Vonoprazan is rapidly absorbed, reaching peak plasma concentration within two hours, and provides prolonged acid suppression¹.

Speaking to Medical Dialogues about the launch, Dr Vikas Gupta, CEO Alkem labs said, "The increase in reflux and acid-peptic diseases, caused by modern diets and lifestyles, is a major concern. With the launch of Vonzai, Alkem’s foothold in the gastrointestinal market is set to grow even further. Vonoprazan’s novel mechanism of action will enable us to enhance treatment and provide much-needed relief for millions of patients facing gastro-related health challenges in India".

He also added, “Alkem’s strong presence in the GI segment, supported by its dedicated Gastrokem division and robust distribution network of Alkem, reinforces our commitment to improving patient care and outcomes. With the launch of Vonzai, we are taking a significant step forward in offering innovative treatment options for millions of patients suffering from GI disorders”.

Alkem Laboratories Limited, a global pharmaceutical company headquartered in Mumbai, India, specializes in the production and distribution of generic pharmaceuticals formulations, and nutraceuticals across both domestic and international markets.

Reference:

1. Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022 Dec;37(12):2217-2228. doi: 10.1111/jgh.16017.